Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| IREN | Tempus AI | Kioxia Holdings | |
|---|---|---|---|
| Moat rating | none The FY2026 10-K (filed 2026-08-27) shows IREN holds an input the industry competes on: it names 'access to secured and energized power' first among what it believes are the principal competitive factors in its industry, and reports 'executed grid connection agreements, letters of agreement or equivalents representing approximately 5GW of total power capacity' in the United States, Canada, Spain and Australia as of June 30, 2026. It does not claim an advantage over rivals in that input. It says 'Certain competitors may have access to more competitively priced power, a greater access to power and a better capacity to timely secure grid connections,' and 'Many of our competitors have greater financial, technical or commercial resources, longer cloud operating histories or larger customer bases, compared to us.' Operating AI Cloud Services capacity was approximately 40MW at June 30, 2026, and the stored XBRL fundamentals from this 10-K show an FY2026 operating loss of about $1,046.7M on revenue of about $707.0M, so no durable advantage is yet demonstrated. | narrow The FY2025 10-K documents a real asset: a network "connected in some way to more than 55% of all oncologists practicing in the United States" and "more than 65% of all academic medical centers," via "more than 700 unique data connections" across "more than 5,000 healthcare institution sites," with "broad data rights, including the rights to longitudinally updated data." Not eroding: revenue $693.4M to $1,271.8M (+83%), net loss narrowed from $705.8M to $245.0M. Not wide: still loss-making against "an accumulated deficit of $2.4 billion," with payment received on only "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests." | narrow Kioxia's FY2025 Annual Securities Report (dated 2026-06-24) describes a real but bounded position. It records 'the limited number of major competitors in the flash memory business', and says its three manufacturing joint ventures with Sandisk let it 'make investments on a larger scale than if it were to invest alone and enjoy economies of scale in terms of capital expenditures and production efficiency'. Against that, the same Risk Factors section describes 'heavy global competition as advanced technologies are necessary for business execution', says 'in the flash memory market the Group's ability to decide prices is limited', that 'Some competitors possess technologies that the Group does not have, such as DRAM' and 'have greater financial strength than the Group', and records that the Group cut production from October 2022 to March 2024. Scale in a small field, not a barrier that protects Kioxia's returns through the cycle. |
| Moat type | none The FY2026 10-K's asserted advantage is control from owning its data centers, 'including the associated land, grid connections and substations', which it believes allows it 'to benefit from more sustainable cash flows and operational flexibility relative to operators that rely upon third-party colocation services or short-term land leases'. Its only scale language is a belief that its 'procurement scale, deployment experience and direct control over the data center layer' lets it bring new compute into service 'rapidly and at scale', a deployment-speed claim, and it 'generally target[s]' regions with 'low-cost and attractive renewable energy sources', a siting target rather than a demonstrated cost position. It does not claim a cost or scale lead: it says 'Many of our competitors are larger, have longer operating histories and significantly greater resources than we do' and that certain competitors 'may have access to more competitively priced power, a greater access to power and a better capacity to timely secure grid connections.' There is no network effect or lock-in either, since existing contracts have 'terms ranging from month to month up to five years'. No enumerated moat source is grounded. | network effects The filing states the mechanism: "Each product line is designed to enable and enhance the other, thereby creating network effects." That is the filing's own characterisation, so the rating rests on corroborating facts: 700+ data connections across 5,000+ sites with longitudinal rights; roughly 801,000 tests in FY2025 (about 340,500 Oncology) feeding the records Insights licenses; Insights working with "19 of the 20 largest public pharmaceutical companies based on 2024 revenue" at "approximately 126%" net revenue retention. Intangibles fit less well: the xT PMA, ADLT status, Paige's clearance and five CAP/CLIA labs are real, but named peers hold comparable approvals. | cost scale The advantage the company itself names is scale and capital efficiency. The Annual Securities Report says the Sandisk joint ventures, which procure the production equipment installed at Kioxia's Yokkaichi and Kitakami plants and 'sell 50% of their products to the Group and 50% to the Sandisk Group', let it 'enjoy economies of scale in terms of capital expenditures and production efficiency'. At its 2026 Investor Day (2026-06-02) management said that 'by leveraging our world-leading economies of scale, we have maintained a lower cost per gigabyte than the industry average', on a slide that cites the TechInsights NAND Market Report Q2 2026 as its source. The filing describes its technology work (layer stacking for BiCS FLASH, the move to QLC) and names 'a decline in competitiveness in production efficiency per gigabyte' as a risk if it falls behind. It does not present that technology as protected IP that rivals cannot match. |
| Leadership | behind The 10-K lists IREN's competitors as hyperscalers (Amazon Web Services, Google Cloud, Microsoft Azure, Oracle Cloud) and specialized AI Cloud Services providers (CoreWeave, Nebius, Crusoe, Lambda, Nscale, SpaceX and others). It says IREN began providing AI Cloud Services in 2024 and cites its 'shorter operating history in AI Cloud Services relative to some competitors', and states 'Some of our competitors have longer operating histories, larger customer bases, more comprehensive IP portfolios and patent protections, more design wins, and greater financial, sales, marketing and distribution resources than we do.' Operating AI Cloud Services capacity was approximately 40MW at June 30, 2026. The filing describes a smaller, later entrant that trails some competitors on operating history, customer base and resources, with its progress so far resting on two anchor contracts (a ~$9.7B five-year Microsoft agreement and a ~$3.4B five-year NVIDIA contract) rather than any claimed category position. | at parity The filing claims no ranked lead; its positional language is hedged, as in "one of the largest sequencers of cancer patients... in the United States." Two disclosures cut the other way: the reimbursement goal is to become "more in line with other NGS providers who have adopted similar strategies, such as FMI and Guardant," and competitors "may have longer operating histories; larger customer bases; greater brand recognition and market penetration." Competition names Foundation Medicine (Roche), Caris, Guardant, Natera, Neogenomics, Quest, LabCorp, Flatiron, IQVIA, ConcertAI and major CROs, all unranked. Scaled positions on both sides support parity, not a top position. | at parity TrendForce's 2Q26 NAND Flash ranking (2026-08-18) puts Kioxia fourth with revenue of about $10.72 billion. Its 13.6% share 'edged down', and it sits behind Samsung (29.3%), SK hynix Group and Micron, which moved up to third. TrendForce's 2Q26 enterprise SSD ranking (2026-09-01) also places it fourth, at $4.64 billion. On technology it is keeping pace: it began sampling the 332-layer 10th-generation BiCS FLASH on 2026-07-03, per its press release. The Annual Securities Report concedes that some competitors 'possess technologies that the Group does not have, such as DRAM' and 'have greater financial strength than the Group'. Kioxia is in the middle of a small group of peers. |
| Pricing power | weak The 10-K's risk factors state 'Our competitors' products, services and technologies may be cheaper or provide better functionality or features than ours, which has resulted and may in the future result in lower-than-expected selling prices or demand for our products.' They also say long-term contract pricing 'is generally fixed or agreed at the time of contracting', so if market pricing for comparable capacity rises during a contract's term 'we will not benefit from those increases with respect to capacity already committed under our existing long-term contracts', and that if customers suffer a downturn or discontinue its services it 'may be compelled to offer more flexible terms, lower our prices or risk losing a significant customer.' The stored XBRL fundamentals from this 10-K show FY2026 revenue of about $707.0M against an operating loss of about $1,046.7M, so there is no margin record yet that evidences pricing power. | weak Diagnostics prices are administered: after a CPT code is set, "CMS, establish payment levels and coverage rules under Medicare," delegating to MACs, while "Private payers establish their rates and coverage rules independently." Average revenue per Oncology test rose from about $1,510 to about $1,600, "driven primarily by increased Medicare reimbursement rates" — the payer moved the price. Collection came on "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests," and payer "cost-saving initiatives... are likely to result in pricing pressures." The moderate pocket is confined to Data and applications ($316.4M of $1,271.8M). | weak The Annual Securities Report states that 'in the flash memory market the Group's ability to decide prices is limited, and in the medium- to long-term selling prices on a bit basis may decline at a similar pace as in the past'. Current margins follow the market. The first-quarter FY2026 results attribute the revenue jump primarily to 'a significant increase in average selling prices (ASPs) resulting from strong demand from data center customers focusing on generative AI'. Gross profit was ¥1,380,066 million on revenue of ¥1,767,117 million, against ¥71,179 million on ¥342,799 million a year earlier. In the 2026 Investor Day Q&A management said it believes 'market pricing will continue to reflect those supply-demand conditions'. |
| Summary | Per its FY2026 10-K, IREN is a vertically integrated AI Cloud Services platform that owns the data center, compute and software layers, underpinned by executed grid connection agreements, letters of agreement or equivalents representing ~5GW and a further multi-GW development pipeline. Its commercial record is concentrated: a five-year Microsoft agreement (~$9.7B total contract value, Horizon 1 delivered and accepted in August 2026, Horizons 2-4 targeted for delivery in phases in calendar Q4 2026) and a five-year ~$3.4B NVIDIA cloud contract together make up a substantial majority of contracted revenue. It holds NVIDIA Preferred Partner and Exemplar Cloud status (HGX B300 and GB300 NVL72) and a strategic partnership intended to support the deployment over time of up to 5GW of NVIDIA DSX-aligned infrastructure, which the filing cites among arrangements that are non-binding or subject to conditions, with no assurance as to the extent of deployments. Against that, the filing names hyperscaler and specialized competitors (AWS, Google Cloud, Azure, Oracle, CoreWeave, Nebius, Crusoe, Lambda, Nscale, SpaceX), many of which it says have greater resources, customers that can use or develop their own solutions, and possible delays to Texas energization from changes to ERCOT's Batch Zero procedures, so the power position is not a demonstrated advantage over rivals and its value depends on execution. | Tempus AI's durable asset is an installed provider network and the longitudinal data rights attached to it, not any single assay: connections to more than 55% of practicing U.S. oncologists and more than 65% of academic medical centers, 700+ data connections across 5,000+ institution sites. That network makes the linked clinical-molecular database sellable — Insights serves 19 of the 20 largest public pharmaceutical companies by 2024 revenue at roughly 126% net revenue retention, and the trial network (1,400+ trials signed, 40,000+ patients identified) depends on the sequencing base. Economics are improving: revenue up 83% to $1.27B, net loss down from $705.8M to $245.0M. It stops short of wide on the filing's own terms — a $2.4B accumulated deficit, payment on only ~55% of oncology and ~50% of hereditary tests, and Diagnostics prices set by CMS, MACs and private payers. | Kioxia calls itself 'a specialized flash memory manufacturer'. It makes BiCS FLASH 3D NAND at Yokkaichi and Kitakami in Japan through three manufacturing joint ventures with Sandisk, whose output is sold 50% to Kioxia and 50% to Sandisk. FY2025 (year to March 2026) revenue was ¥2,337.6bn: SSD & Storage ¥1,362.6bn, Smart Devices ¥760.0bn and Other ¥215.0bn, with the Apple group alone at 20.4% of sales. Its moat is scale in a concentrated industry. TrendForce ranks it fourth in 2Q26 NAND revenue with a 13.6% share, and in August 2026 the partners announced anticipated investments in Japan of over $31 billion through 2032, contingent on government support. The same filing sets out the limits: limited ability to set prices; rivals that also make DRAM and have more financial strength; China's government-supported push for domestic semiconductor production; and a joint-venture agreement effective until 2034, with no decision yet on whether it continues after that. First-quarter FY2026 gross profit was ¥1,380,066 million on revenue of ¥1,767,117 million, against ¥71,179 million on ¥342,799 million a year earlier. The company attributes the jump primarily to a significant increase in average selling prices. |
| Chain position | Downstream AI-cloud operator: owns grid-connected data centers and deploys NVIDIA/AMD GPU systems it rents to hyperscalers, frontier labs, AI developers and enterprises (anchor customers Microsoft and NVIDIA). | Tempus sits between clinical care and pharma R&D. It ingests data from 5,000+ institution sites, runs five CAP/CLIA labs (Chicago, Atlanta, Raleigh, Aliso Viejo, Minneapolis via OneOme), and sells Diagnostics to providers and payers ($955.4M FY2025, +111%, administered) and Data and applications to pharma ($316.4M, +31%, negotiated). The clinical output is the data business's input. | Upstream NAND flash and SSD supplier. The filing says much of its revenue 'depends on a limited number of customers and industries, such as major smartphone manufacturers and large IT companies, including hyperscalers that require SSDs'. The Apple group was 20.4% of FY2025 sales. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | -0.20 at weight 0.20 · swarm bearish Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. |